查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1406798

脑癌诊断市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按诊断类型、肿瘤类型、最终用户、地区和竞争细分

Brain Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnostic Type, By Tumor Type, By End User, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球脑癌诊断市场价值为 25.6 亿美元，预计在预测期内将出现令人印象深刻的成长，到 2028 年复合CAGR为3.36%。全球脑癌诊断市场是更广泛的医疗保健领域中一个充满活力且快速发展的领域产业。它包括旨在诊断和检测脑癌的各种产品和服务，脑癌是一种以大脑细胞异常生长为特征的危及生命的疾病。

主要市场驱动因素

脑癌发生率上升

市场概况
预测期 2024-2028
2022 年市场规模 25.6亿美元
2028 年市场规模 31亿美元
2023-2028 年CAGR 3.36%
成长最快的细分市场 医院
最大的市场 北美洲

全球脑癌发生率呈上升趋势，对全球健康构成重大挑战。在这一令人担忧的趋势中，脑癌诊断领域的需求正在激增，因为早期检测对于对抗这种致命疾病至关重要。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 按诊断类型
    • 按肿瘤类型
    • 按最终用户
    • 按地区

第 6 章：北美脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲脑癌诊断市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依诊断类型（影像学检查、腰椎穿刺、切片、分子检测等）
    • 依肿瘤类型（转移性、脑膜瘤、胶质母细胞瘤、脑下垂体内瘤、其他）
    • 按最终使用者（医院、诊断中心、其他）
    • 按国家/地区
  • MEA：国家分析
    • 南非脑癌诊断
    • 沙乌地阿拉伯脑癌诊断
    • 阿联酋脑癌诊断
    • 科威特脑癌诊断

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • GE Healthcare Inc
    • Koninklijke Philips NV
    • Siemens Healthineers AG
    • Fujifilm Corp
    • Hitachi, Ltd.
    • Hologic Inc
    • NantOmics LLC
    • Thermo Fisher Scientific Inc

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 19539

Global Brain Cancer Diagnostics Market has valued at USD 2.56 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 3.36% through 2028. The Global Brain Cancer Diagnostics Market is a dynamic and rapidly evolving sector within the broader healthcare industry. It encompasses the various products and services aimed at diagnosing and detecting brain cancer, a life-threatening condition characterized by the abnormal growth of cells in the brain.

Key Market Drivers

Rising Incidence of Brain Cancer

Market Overview
Forecast Period2024-2028
Market Size 2022USD 2.56 Billion
Market Size 2028USD 3.10 Billion
CAGR 2023-20283.36%
Fastest Growing SegmentHospitals
Largest MarketNorth America

The global incidence of brain cancer is on the rise, posing a significant health challenge worldwide. Amid this concerning trend, the field of brain cancer diagnostics is witnessing a surge in demand, as early detection becomes paramount in the battle against this deadly disease.

An aging global population has led to an increased prevalence of brain cancer, as the risk of developing the disease tends to rise with age. The demographic transition towards older populations in many countries has contributed to this upward trend. Exposure to environmental carcinogens and toxins, such as radiation and certain chemicals, has been linked to an increased risk of brain cancer. These factors are more prevalent in modern society, leading to higher incidences of the disease. Some individuals may have a genetic predisposition to brain cancer. Genetic mutations and family history can play a role in the development of brain tumors, contributing to the overall incidence. Advancements in medical imaging and diagnostic technologies have made it easier to detect brain cancer at an earlier stage. This has led to a higher number of diagnoses, particularly for tumors that may have gone undetected in the past.

With more individuals being diagnosed with brain cancer, there is a growing demand for diagnostic services. Medical professionals are increasingly relying on advanced imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, to accurately diagnose and stage brain tumors. Early detection of brain cancer is crucial for improving treatment outcomes and patient survival rates. The rising incidence of the disease has prompted healthcare providers to prioritize early screening and diagnosis, driving the adoption of brain cancer diagnostic tools. As the number of brain cancer cases grows, so does the need for personalized treatment plans. Accurate diagnosis allows for tailored therapies that consider the specific type and stage of the tumor, leading to more effective treatments. The increasing prevalence of brain cancer has spurred investment in research and development efforts. Pharmaceutical companies, diagnostic equipment manufacturers, and research institutions are dedicating resources to developing innovative diagnostic technologies and treatment modalities. The rising incidence of brain cancer has led to heightened awareness campaigns and educational initiatives. These efforts aim to inform the public about the importance of early detection and the availability of advanced diagnostic tools.

Advancements in Imaging Technologies

The field of brain cancer diagnostics is undergoing a profound transformation, thanks to significant advancements in imaging technologies. These innovations are playing a pivotal role in early detection, precise characterization, and effective treatment planning for brain cancer patients.

Imaging technologies have long been at the forefront of brain cancer diagnostics. They allow healthcare professionals to visualize the brain's internal structures, detect abnormalities, and monitor the progression of brain tumors. Early and accurate diagnosis is paramount in the fight against brain cancer, as it enables timely intervention and improved patient outcomes.

MRI has evolved into one of the most crucial tools in brain cancer diagnostics. Recent advancements have resulted in higher resolution images, improved contrast, and faster scanning times. Functional MRI (fMRI) and diffusion tensor imaging (DTI) are also used to assess brain function and connectivity, providing valuable information for treatment planning. CT scans remain a cornerstone in brain cancer diagnosis. Modern CT technology offers better image clarity and reduced radiation exposure, making it safer and more efficient for patients. CT perfusion imaging is used to evaluate blood flow in the brain, aiding in tumor assessment. PET scans combined with CT or MRI provide valuable insights into brain cancer metabolism. They help differentiate between benign and malignant tumors, detect recurrence, and monitor treatment response. Advancements in PET technology has improved image quality and accuracy. SRS combines high-resolution imaging with precise radiation therapy delivery. It is used to treat brain tumors non-invasively, sparing healthy tissue. Advanced SRS systems, such as Gamma Knife and CyberKnife, enhance treatment precision and patient comfort. Functional imaging techniques like MR spectroscopy and perfusion imaging offer insights into tumor biology and vascularity. These technologies assist in differentiating tumor types and assessing treatment response.

Advanced imaging technologies enable earlier and more accurate diagnosis of brain tumors. This not only improves survival rates but also reduces the complexity of treatment. Detailed imaging data helps healthcare providers tailor treatment plans to each patient's unique needs. This precision medicine approach enhances treatment efficacy and minimizes side effects. The demand for more advanced imaging tools has fueled research and development efforts in the medical imaging industry. Companies are continuously innovating to improve imaging quality, reduce scan times, and enhance patient comfort. Imaging technologies are not limited to initial diagnosis; they also play a crucial role in monitoring treatment response and detecting recurrences. This ongoing need for imaging services sustains the growth of the diagnostics market. Advancements in imaging technologies are becoming more accessible worldwide, including in low-resource settings. This broader access contributes to market growth as it expands the reach of brain cancer diagnostics.

Molecular Diagnostics and Biomarkers

In the ongoing battle against brain cancer, the emergence of molecular diagnostics and the discovery of biomarkers have brought about a transformative shift in the landscape of brain cancer diagnostics. These cutting-edge technologies are playing a pivotal role in early detection, accurate classification, and personalized treatment strategies for brain cancer patients.

Molecular diagnostics can differentiate between various subtypes of brain tumors, such as glioblastoma, astrocytoma, or oligodendroglioma. This distinction is vital for determining the most appropriate treatment strategy. By analyzing biomarkers, healthcare providers can tailor treatments to the unique genetic and molecular profile of a patient's tumor. This approach maximizes treatment efficacy while minimizing side effects. Biomarkers provide valuable information about the aggressiveness of the tumor and the patient's likely prognosis. This information helps guide clinical decision-making. Molecular diagnostics and biomarkers enable continuous monitoring of treatment response. Changes in the molecular profile of a tumor can indicate whether a therapy is effective or if adjustments are needed.

The advent of molecular diagnostics and biomarkers has ushered in the era of precision medicine for brain cancer. This approach maximizes treatment effectiveness while minimizing unnecessary interventions, making it an attractive option for both patients and healthcare providers. Biomarkers can facilitate the early detection of brain cancer. Some biomarkers can be detected in bodily fluids, such as blood or cerebrospinal fluid, allowing for non-invasive and potentially routine screening. Personalized treatment plans based on molecular profiling and biomarker analysis are associated with improved patient outcomes. This success is driving the adoption of these technologies in clinical practice. Molecular diagnostics and biomarkers play a pivotal role in brain cancer research and drug development. They help identify potential therapeutic targets and assess the effectiveness of experimental treatments. By tailoring treatments to individual patients, molecular diagnostics and biomarkers can help reduce healthcare costs associated with ineffective or unnecessary therapies. Patients are increasingly seeking personalized treatment options, and the availability of molecular diagnostics and biomarkers empowers them to be more engaged in their healthcare decisions. As the utility and relevance of these technologies become more evident, the global brain cancer diagnostics market is expanding. Companies specializing in molecular diagnostics and biomarker development are experiencing significant growth.

Awareness and Early Detection Campaigns

The global fight against brain cancer has intensified in recent years, thanks in large part to concerted efforts to raise awareness and promote early detection. These campaigns are not only crucial for improving patient outcomes but also have a significant impact on the growth of the global brain cancer diagnostics market.

Brain cancer is a complex and life-threatening condition that requires early intervention for the best possible outcomes. Awareness campaigns play a vital role in educating the public about the signs and symptoms of brain cancer, emphasizing the importance of early diagnosis and encouraging individuals to seek medical attention promptly.

These campaigns disseminate information about brain cancer, its risk factors, and the importance of early detection. They often target both the general public and healthcare professionals. Raising awareness about the early warning signs of brain cancer, such as persistent headaches, seizures, vision changes, and cognitive impairments, can lead to earlier medical consultations. These campaigns may promote the availability of screening and diagnostic services, providing individuals with convenient access to brain cancer diagnostics. Brain cancer advocacy groups and organizations play a significant role in advancing awareness and early detection efforts. They collaborate with healthcare providers, policymakers, and the public to drive change. Campaigns often highlight support networks and resources available to individuals diagnosed with brain cancer, offering emotional and practical assistance.

Awareness campaigns prompt individuals to seek medical attention if they experience symptoms associated with brain cancer. As a result, there is a higher demand for diagnostic services, including imaging and biomarker testing. Early detection campaigns lead to earlier diagnoses, which is crucial for effective treatment planning. This emphasis on early intervention can lead to more favorable outcomes for patients. The growing awareness of brain cancer and the need for early detection drives investments in research and development of new diagnostic technologies, including innovative imaging techniques and biomarkers. Awareness campaigns often highlight the need for improved healthcare infrastructure, including diagnostic facilities and specialized expertise, which can lead to investments and expansions in the healthcare sector. Campaigns and initiatives with a global scope are instrumental in increasing awareness and access to brain cancer diagnostics, even in regions with historically limited resources. Increased public awareness can lead to greater funding and philanthropic support for brain cancer research and diagnostic initiatives.

Key Market Challenges

Complexity of Brain Cancer

Brain cancer is a complex and heterogeneous disease. There are various types of brain tumors, each with distinct characteristics and behaviors. This complexity makes accurate diagnosis and classification challenging, as one-size-fits-all approaches are often inadequate. Addressing this challenge requires advanced diagnostic techniques and a deeper understanding of tumor biology.

Limited Biomarkers

While biomarkers are valuable tools in diagnosing and managing cancer, the availability of specific and reliable biomarkers for brain cancer is limited compared to other types of cancer. Identifying biomarkers unique to brain cancer is crucial for early detection and treatment planning. Researchers are actively working to discover and validate new biomarkers.

High Diagnostic Costs

Advanced brain cancer diagnostic technologies, such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, can be costly. These expenses can place a significant burden on healthcare systems and patients, limiting access to timely and accurate diagnostics. Efforts to reduce costs and improve affordability are essential for broader accessibility.

Key Market Trends

Precision Medicine and Biomarker-Based Diagnosis

Precision medicine is becoming a cornerstone of brain cancer diagnostics. As our understanding of the genetic and molecular basis of brain tumors deepens, the use of biomarkers for diagnosis and treatment planning is gaining prominence. The identification of specific genetic alterations and biomarkers associated with brain cancer subtypes allows for tailored therapies, enhancing treatment outcomes.

Liquid Biopsies

Liquid biopsies, a non-invasive diagnostic approach that involves analyzing circulating tumor DNA (ctDNA) in bodily fluids like blood or cerebrospinal fluid, are gaining traction in brain cancer diagnostics. These tests can provide real-time insights into tumor progression, monitor treatment response, and detect tumor recurrence. Liquid biopsies are poised to revolutionize brain cancer diagnosis by offering a less invasive and more accessible alternative to traditional tissue biopsies.

Multimodal Imaging

Multimodal imaging techniques, which combine various imaging modalities such as MRI, PET, and CT scans, are on the rise. These comprehensive approaches provide a more holistic view of brain tumors, allowing for better tumor localization, characterization, and treatment planning. The fusion of imaging data with molecular and genetic information enhances diagnostic accuracy.

Segmental Insights

Diagnostic Type Insights

Based on the category of Diagnostic Type, it is anticipated that the Imaging Tests sector will maintain a significant market share during the forecast years. This can be attributed to the growing adoption of Magnetic resonance imaging (MRI). MRI is a radiological medical imaging method used to generate images of anatomical structures and physiological processes within the body. These images play a crucial role in identifying and diagnosing abnormalities within the body. The MRI segment stands out as the dominant player in this market due to its extensive use in the diagnosis of brain tumors. The increasing global incidence of brain cancer cases is expected to fuel the demand for brain tumor diagnostics in the foreseeable future. As an example, according to the Canadian Cancer Society's May 2022 update, it was projected that in 2022, 3,200 Canadians would receive diagnoses of brain and spinal cord cancer, with 1,850 cases among men and 1,350 among women.

Additionally, the growing adoption of MRI systems can be attributed to the establishment of new facilities in various countries worldwide. For instance, in November 2021, a state-of-the-art MRI facility was inaugurated at the National Brain Research Centre (NBRC) in Manesar, Haryana, India. The NBRC is India's premier institute dedicated to neuroscience research and education, and it installed a Siemens PRISMA 3T MRI Scanner at this facility.

Furthermore, in February 2023, Case Western Reserve University received a USD 3 million grant to advance innovative MRI technology and software for the diagnosis of brain tumors. This development is expected to enable personalized treatment planning, ultimately leading to improved outcomes for patients.

Tumor Type Insights

Based on Tumor Type, Glioblastoma, a highly aggressive and malignant form of brain cancer, is poised to exert a dominant influence on the Global Brain Cancer Diagnostics Market in 2022. Several key factors contribute to this prominence. Firstly, glioblastoma represents a substantial portion of all brain cancer cases, making it a focal point for diagnostic advancements and research. Additionally, the complex nature of glioblastoma necessitates advanced diagnostic tools and technologies, driving innovation within the market. Furthermore, the rising global incidence of glioblastoma cases underscores the critical need for accurate and early diagnosis, which in turn fuels the demand for brain cancer diagnostics. As healthcare providers and researchers continue to focus on enhancing detection methods and treatment options for glioblastoma, its dominant position in the Global Brain Cancer Diagnostics Market is expected to persist and even grow in the coming years.

Regional Insights

In 2022, North America is poised for substantial growth in the market. Specifically, the North American brain tumor diagnostics market is expected to exhibit significant expansion during the forecast period, with the United States taking the lead. This leadership position can be attributed to the well-developed healthcare industry in the region and the increasing awareness among the population about advanced diagnostic technologies. For instance, data from the American Brain Tumor Association reveals that in 2021, over 84,000 individuals received primary brain tumor diagnoses, resulting in approximately 18,000 deaths due to primary malignant brain tumors. Moreover, the same source indicates that more than 28,000 children in the United States were diagnosed with brain tumors in 2021. The growing incidence of brain tumors is anticipated to be a driving force behind the region's market growth.

Furthermore, the introduction and deployment of state-of-the-art diagnostic devices in the country by key market players are expected to further boost market growth in the region. For example, in December 2021, ADM Diagnostics Inc. obtained FDA clearance for CorInsights MRI, a tool that provides quantitative data on brain tissue volume, catering to radiologists, neurologists, and clinical researchers. Such product launches are playing a pivotal role in propelling market expansion within the region.

Key Market Players

GE Healthcare Inc

Koninklijke Philips NV

Siemens Healthineers AG

Fujifilm Corp

Hitachi, Ltd.

Hologic Inc

NantOmics LLC

Thermo Fisher Scientific Inc

Report Scope:

In this report, the Global Brain Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Brain Cancer Diagnostics Market, By Diagnostic Type:

  • Imaging Test
  • Lumbar Puncture
  • Biopsy
  • Molecular Testing
  • Others

Brain Cancer Diagnostics Market, By Tumor Type:

  • Metastatic
  • Meningioma
  • Glioblastoma
  • Pituitary Endoma
  • Others

Brain Cancer Diagnostics Market, By End User:

  • Hospitals
  • Diagnostics Centers
  • Others

Brain Cancer Diagnostics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Brain Cancer Diagnostics Market.

Available Customizations:

  • Global Brain Cancer Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Brain Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 5.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 5.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Diagnostic Type
    • 5.3.2. By Tumor Type
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Brain Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 6.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 6.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Brain Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnostic Type
        • 6.3.1.2.2. By Tumor Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Brain Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnostic Type
        • 6.3.2.2.2. By Tumor Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Brain Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnostic Type
        • 6.3.3.2.2. By Tumor Type
        • 6.3.3.2.3. By End User

7. Europe Brain Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 7.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 7.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Brain Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnostic Type
        • 7.3.1.2.2. By Tumor Type
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Brain Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnostic Type
        • 7.3.2.2.2. By Tumor Type
        • 7.3.2.2.3. By End User
    • 7.3.3. France Brain Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnostic Type
        • 7.3.3.2.2. By Tumor Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Brain Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnostic Type
        • 7.3.4.2.2. By Tumor Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Brain Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnostic Type
        • 7.3.5.2.2. By Tumor Type
        • 7.3.5.2.3. By End User

8. Asia-Pacific Brain Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 8.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 8.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Brain Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnostic Type
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Japan Brain Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnostic Type
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By End User
    • 8.3.3. India Brain Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnostic Type
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Australia Brain Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnostic Type
        • 8.3.4.2.2. By Tumor Type
        • 8.3.4.2.3. By End User
    • 8.3.5. South Korea Brain Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnostic Type
        • 8.3.5.2.2. By Tumor Type
        • 8.3.5.2.3. By End User

9. South America Brain Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 9.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 9.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Brain Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnostic Type
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Brain Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnostic Type
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Brain Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnostic Type
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Brain Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 10.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 10.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Brain Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnostic Type
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Brain Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnostic Type
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Brain Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnostic Type
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By End User
    • 10.3.4. Kuwait Brain Cancer Diagnostics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Diagnostic Type
        • 10.3.4.2.2. By Tumor Type
        • 10.3.4.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. GE Healthcare Inc
    • 14.6.2. Koninklijke Philips NV
    • 14.6.3. Siemens Healthineers AG
    • 14.6.4. Fujifilm Corp
    • 14.6.5. Hitachi, Ltd.
    • 14.6.6. Hologic Inc
    • 14.6.7. NantOmics LLC
    • 14.6.8. Thermo Fisher Scientific Inc

15. Strategic Recommendations

16. About Us & Disclaimer